Effect of topical prostaglandins on the biomechanics and shape of the cornea.
Corneal biomechanics
Corneal shape
Corneal tomography
Prostaglandins
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
22
05
2019
accepted:
06
08
2019
revised:
09
07
2019
pubmed:
12
8
2019
medline:
23
1
2020
entrez:
12
8
2019
Statut:
ppublish
Résumé
To investigate the effect of topical prostaglandin (PG) eyedrops on the biomechanics and shape of the cornea. Consecutive patients with primary open-angle glaucoma who had been treated with the same anti-glaucoma PG (114 eyes, 57 patients) or β-blocker (36 eyes, 18 patients) eyedrops in 1 eye alone for more than 3 months at Inouye Eye Hospital or Miyata Eye Hospital. The biomechanical properties of the cornea were measured using a Corvis ST device (Oculus, Wetzlar, Germany). Corneal tomography was measured with a Casia 1 or 2 (Tomey Corp., Nagoya, Japan). The biomechanical parameters and tomographic features of the cornea were compared between PG-treated eyes, β-blocker-treated eyes, and contralateral eyes using a mixed-effect model adjusted for intraocular pressure and corneal thickness and a linear model adjusted for age, sex, intraocular pressure, and corneal thickness. The PG-treated eyes had a significantly smaller applanation 1 time, the highest concavity radius, and a larger deformation amplitude than the contralateral eyes. Also, the PG-treated eyes had a significantly smaller applanation 1 time and applanation 2 velocity but a larger peak distance than the β-blocker-treated eyes. There were no significant differences in any of the Casia parameters between the PG-treated eyes and the contralateral eyes. The results of this study suggest that topical PG makes biochemical changes to the cornea but does not alter its shape.
Identifiants
pubmed: 31401684
doi: 10.1007/s00417-019-04435-7
pii: 10.1007/s00417-019-04435-7
doi:
Substances chimiques
Prostaglandins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2213-2219Références
PLoS One. 2016 May 17;11(5):e0155527
pubmed: 27187282
Arch Ophthalmol. 2010 Apr;128(4):466-71
pubmed: 20385943
Curr Eye Res. 1996 Aug;15(8):869-75
pubmed: 8921230
Invest Ophthalmol Vis Sci. 2015 Feb 03;56(2):738-50
pubmed: 25648341
Jpn J Ophthalmol. 2008 Jul-Aug;52(4):334-336
pubmed: 18773275
Br J Ophthalmol. 2017 Feb;101(2):120-125
pubmed: 27162226
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5557-65
pubmed: 26305527
Exp Eye Res. 2012 Jan;94(1):13-21
pubmed: 22067128
Ophthalmology. 2005 Apr;112(4):654-9
pubmed: 15808258
Optom Vis Sci. 2018 Jul;95(7):608-615
pubmed: 29957740
Invest Ophthalmol Vis Sci. 1997 Dec;38(13):2772-80
pubmed: 9418730
J Curr Ophthalmol. 2017 May 22;29(3):175-181
pubmed: 28913507
J Cataract Refract Surg. 2017 Oct;43(10):1271-1280
pubmed: 29120713
Invest Ophthalmol Vis Sci. 1997 Oct;38(11):2214-23
pubmed: 9344344
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5182-8
pubmed: 14638715
Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20
pubmed: 19038618
Invest Ophthalmol Vis Sci. 2014 May 15;55(6):3651-9
pubmed: 24833745